ResMed '2030 Strategy' aims for high-single-digit revenue growth.

JHVEPhoto ResMed ( NYSE: RMD ) after Monday's closing bell unveiled its "2030 Strategy," a plan to boost growth and profitability. The maker of sleep apnea devices said its five-year financial outlook projects high-single-digit revenue growth and earnings growth higher than revenue growth. The.